Last reviewed · How we verify
NCT05857514
Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis
NA trial testing Rectal Indomethacin in Post-ERCP Acute Pancreatitis in 384 participants. Status unknown.
1 May 2024
Quick facts
| Lead sponsor | Moti Lal Nehru Medical College |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 384 |
| Start date | 10 May 2023 |
| Primary completion | 1 May 2024 |
| Estimated completion | 1 May 2024 |
| Sites | 2 locations across India |
Drugs / interventions tested
- Rectal Indomethacin — full drug profile →
- Prophylactic Pancreatic duct stenting
Conditions studied
- Post-ERCP Acute Pancreatitis — all drugs for Post-ERCP Acute Pancreatitis →
Sponsor
Moti Lal Nehru Medical College
Who can join
Adults 18 to 65, any sex, with Post-ERCP Acute Pancreatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to compare rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis. The main question it aims to answer is: whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis Participants will be patients who give consent to the study and who are required to undergo ERCP as part of their standard care. If there is a comparison group: Researchers will compare \[rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis.\] to see if \[whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis\].
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05857514
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post-ERCP Acute Pancreatitis
Currently open trials in the same condition.
- NCT07117318 — Rectal NSAIDs With/Without PD Stent for PEP Prevention · NA · recruiting
- NCT06260878 — Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis · Phase 4 · recruiting
- NCT05267379 — An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreati · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05857514 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Moti Lal Nehru Medical College
- Last refreshed: 28 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05857514.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing